Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 10: The Cardiac Channelopathies A Scientific Statement From the American Heart Association and American College of Cardiology by Ackerman, Michael J. et al.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 6 , N O . 2 1 , 2 0 1 5
ª 2 0 1 5 B Y T H E A M E R I C A N H E A R T A S S O C I A T I O N , I N C . A N D
T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N
I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 9 . 0 4 2
P U B L I S H E D B Y E L S E V I E R I N C .AHA/ACC SCIENTIFIC STATEMENTEligibility and Disqualiﬁcation
Recommendations for Competitive Athletes
With Cardiovascular Abnormalities:
Task Force 10: The Cardiac Channelopathies
A Scientiﬁc Statement From the American Heart Association and American College of CardiologyMichael J. Ackerman, MD, PHD, FACC, Chair**On behalf of the American Heart Association Electrocardiography and
Arrhythmias Committee of the Council on Clinical Cardiology, Council on
Cardiovascular Disease in the Young, Council on Cardiovascular and
Stroke Nursing, Council on Functional Genomics and Translational
Biology, and the American College of Cardiology.
The American Heart Association and the American College of Cardi-
ology make every effort to avoid any actual or potential conﬂicts of
interest that may arise as a result of an outside relationship or a per-
sonal, professional, or business interest of a member of the writing
panel. Speciﬁcally, all members of the writing group are required to
complete and submit a Disclosure Questionnaire showing all such re-
lationships that might be perceived as real or potential conﬂicts of
interest. The Preamble and other Task Force reports for these pro-
ceedings are available online at www.onlinejacc.org (J Am Coll Cardiol
2015;66:2343–9; 2350–5; 2356–61; 2362–71; 2372–84; 2385–92; 2393–7;
2398–405; 2406–11; 2412–23; 2429–33; 2434–8; 2439–43; 2444–6; and
2447–50).
This statement was approved by the American Heart Association
Science Advisory and Coordinating Committee on June 24, 2015, and
the American Heart Association Executive Committee on July 22, 2015,
and by the American College of Cardiology Board of Trustees and
Executive Committee on June 3, 2015.Douglas P. Zipes, MD, FAHA, MACC*
Richard J. Kovacs, MD, FAHA, FACC*
Barry J. Maron, MD, FACC*The cardiac channelopathies are a collection of primary,
genetically mediated heart rhythm disorders (also
referred to as the primary electrical disorders) that are
generally associated with a structurally normal heart
and a propensity for syncope, seizures, or sudden car-
diac arrest precipitated by a channelopathy-mediated
episode of nonsustained or sustained polymorphic
ventricular tachycardia (torsade de pointes) or ven-
tricular ﬁbrillation. These cardiac channelopathies
include long-QT syndrome (LQTS), catecholaminergic
polymorphic ventricular tachycardia (CPVT), Brugada
syndrome (BrS), early repolarization syndrome, short-
QT syndrome, and potentially idiopathic ventricularﬁbrillation. Approximately 1 in 1,000 people are
affected by a cardiac channelopathy, with LQTS
being most common, involving an estimated 1 in 2,000
people (1).
Presently, these channelopathies should be viewed
as potentially lethal but highly treatable conditions.
However, unlike the various bradyarrhythmias and
tachyarrhythmias detailed in the Task Force 9 report
(2), there remains signiﬁcant variability and hetero-
geneity among pediatric and adult heart rhythm
specialists in terms of their ability to diagnose, risk
stratify, and treat patients with these conditions. For
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2425a second opinion evaluation at a LQTS specialty center for
a previously rendered diagnosis of LQTS by a heart
rhythm specialist were reclassiﬁed as otherwise normal,
having insufﬁcient evidence to merit that diagnostic
consideration (3). This is explained in part by the
advanced knowledge and training required to evaluate
and treat these less common channelopathies. Accord-
ingly, any return-to-play decision for an athlete suspected
of having a cardiac channelopathy necessitates that the
athlete be evaluated, risk stratiﬁed, treated, and coun-
seled by a heart rhythm specialist or genetic cardiologist
with sufﬁcient experience and expertise in these syn-
dromes (4).
For the most part, restriction from virtually all
competitive sports has been the guideline-based re-
commendation since 2005 for athletes with a cardiac
channelopathy, regardless of the underlying channel-
opathy (5,6). This universal recommendation was given
despite the observation that exercise or competitive
athletics has only been established as a potentially
proarrhythmic trigger for CPVT and LQTS (particularly
LQT1) (7,8).
Since 2005, there have been 4 fundamental de-
velopments that inform these current recommendations.
First, genetic testing is now a widely available clinical test
used routinely in the evaluation of a patient with a sus-
pected channelopathy. The ﬁrst Heart Rhythm Society/
European Heart Rhythm Association–sponsored guideline
as to the clinical use of genetic testing for the cardiac
channelopathies was published in 2011 (9).
Second, despite increased discovery of more family
members (athletes and nonathletes alike) with genotype
positive/phenotype-negative (i.e., concealed disease)
status secondary to the availability and use of genetic
testing, there has been no report of athletes with con-
cealed channelopathic substrates in the United States
experiencing their sentinel event during sport. Thus,
consistent with our expert opinion–based recommenda-
tions from a decade ago, there has been no observa-
tional evidence to support the European position to
disqualify an athlete based solely on a positive genetic
test (5,6).
Nevertheless, it remains prudent for an athlete with
a channelopathy, whether concealed or manifest,
to exercise simple precautionary measures, including
1) avoidance of QT-prolonging drugs for athletes with
LQTS (http://www.crediblemeds.org), 2) avoidance of
drugs that exacerbate the BrS in affected athletes
(http://www.brugadadrugs.org), 3) electrolyte/hydration
replenishment and avoidance of dehydration for all,
4) avoiding/treating hyperthermia from febrile illnesses
or training-related heat exhaustion/heat stroke for ath-
letes with either LQTS or BrS, 5) acquisition of a per-
sonal automatic external deﬁbrillator as part of theathlete’s personal sports safety gear, and 6) establishing
an emergency action plan with the appropriate school/
team ofﬁcials.
Third, observational evidence, derived from a large
series of athletes with either concealed, electrocardio-
graphically manifest, or symptomatic LQTS who chose to
remain competitive despite the 2005 guideline-based
recommendations for their disqualiﬁcation, now exists
(10,11). In this single-center study of LQTS athletes, only
1 of the 130 athletes with LQTS (LQT1 speciﬁcally)
experienced 2 LQT1-triggered events that resulted in
appropriate ventricular ﬁbrillation–terminating implant-
able cardioverter-deﬁbrillator (ICD) therapies while
playing baseball on 1 occasion and soccer on another
occasion in >650 athlete-years of observation. An
important caveat is that every athlete underwent an
extensive 2- to 3-day evaluation that included being
diagnosed, risk stratiﬁed, treated, and counseled by a
single LQTS specialist. This program’s experience has
been reproduced independently in a study involving
sports participation in genotype-positive children at
another center (12).
At this point in time, no similar data exist for athletes
with CPVT. Given that CPVT is likely the channelopathy
most vulnerable to exercise as a proarrhythmic trigger,
the likelihood of a CPVT-triggered breakthrough event
despite b-blocker use is much higher than in LQTS (7), and
the potential for an arrhythmia/ICD storm is greatest in
patients with CPVT (13), competitive sports (beyond class
IA sports) are not recommended for the athlete with CPVT
and documented exercise-induced frequent premature
ventricular contractions/nonsustained ventricular tachy-
cardia. Whether or not such an athlete could be cleared in
the setting of combination drug therapy (for example,
b-blockers and ﬂecainide) or after left cardiac sympathetic
denervation would require consultation with a CPVT
disease specialist.
Fourth, the observational experience from the North
American ICD Sports Registry currently comprising >340
athletes with an ICD suggests that these athletes with an
ICD can continue to participate with negligible mortality
(0 deaths with 31 months’ average follow-up to date)
and no discernible excess in damage to the implanted
device or inappropriate shocks to the patient (13). The
most common heart disease represented among these
athletes with an ICD was LQTS, followed by hypertro-
phic cardiomyopathy and arrhythmogenic right ventric-
ular cardiomyopathy.
Despite these 4 new developments over the past
decade, there remains an overall lack of data or evidence
regarding the true risk that an athlete with a channelop-
athy faces by remaining in competitive sports. As such,
these recommendations are buttressed by only Level of
Evidence C.
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2426For the purposes of this document, a previously
symptomatic athlete describes one who has experienced
at least 1 channelopathy-triggered/suspected syncope,
seizure, or aborted/resuscitated cardiac arrest. On the
other hand, an athlete with a concealed channelopathy
describes an asymptomatic athlete with a positive genetic
test who lacks electrocardiographic evidence on a 12-lead
ECG at rest (i.e., corrected QT interval <460 ms for LQTS,
no spontaneous type 1 Brugada electrocardiographic
pattern in the right precordial leads for BrS, no horizontal
or downsloping early repolarization pattern in the
inferolateral leads for early repolarization syndrome, or
corrected QT interval >380 ms for short-QT syndrome) or
during exercise stress testing for CPVT (i.e., no exercise-
induced premature ventricular contractions in bigeminy,
couplets, or worse). An athlete with a concealed chan-
nelopathy is also referred to as genotype positive/
phenotype negative.
In addition, for the purposes of this document, disease-
speciﬁc treatments may include either drug therapy,
denervation therapy (i.e., left cardiac sympathetic
denervation for LQTS and CPVT), device therapy (gener-
ally an ICD rather than a pacemaker if device therapy is
indicated), or a combination thereof. The athlete’s treat-
ment program should be based primarily on the severity
of the disease phenotype and should not be unduly
inﬂuenced by the patient’s athlete status. In other words,
an ICD should not be implanted just because the patient
happens to be an athlete in order for the patient to remain
an athlete. This individualized treatment program should
be sought from a center or program dedicated to patients
with cardiac channelopathies and implemented by a heart
rhythm specialist or genetic cardiologist with sufﬁcient
experience and expertise with these disorders (4). Finally,
it may be prudent to temporarily restrict an athlete who
experiences a cardiac event and is suspected of having a
channelopathy or the athlete with a known channelop-
athy who experiences a breakthrough cardiac event
for 3 months to ensure adequate time for evaluation,
counseling, and initiation or modiﬁcation of the athlete’s
treatment program.
Recommendations
1. For athletes with a suspected/diagnosed cardiac
channelopathy, a comprehensive evaluation by a
heart rhythm specialist or genetic cardiologist with
sufﬁcient experience and expertise with these disor-
ders is recommended (Class I; Level of Evidence C).
2. It is recommended that symptomatic athletes with
any suspected or diagnosed cardiac channelopathy
be restricted from all competitive sports until a
comprehensive evaluation has been completed, theathlete and his or her family are well informed, a
treatment program has been implemented, and
the athlete has been asymptomatic on therapy for
3 months (Class I; Level of Evidence C).
3. It is reasonable for an asymptomatic athlete with
genotype-positive/phenotype-negative (i.e., concealed
channelopathy) LQTS, CPVT, BrS, early repolarization
syndrome, idiopathic ventricular ﬁbrillation, or short-
QT syndrome to participate in all competitive sports
with appropriate precautionary measures, including
1) avoidance of QT-prolonging drugs for athletes
with LQTS (http://www.crediblemeds.org), 2) avoid-
ance of drugs that exacerbate the BrS in affected ath-
letes (http://www.brugadadrugs.org), 3) electrolyte/
hydration replenishment and avoidance of dehydra-
tion for all, 4) avoidance or treatment of hyperthermia
from febrile illnesses or training-related heat exhaus-
tion or heat stroke for athletes with either LQTS or
BrS, 5) acquisition of a personal automatic external
deﬁbrillator as part of the athlete’s personal sports
safety gear, and 6) establishment of an emergency
action plan with the appropriate school or team
ofﬁcials (Class IIa; Level of Evidence C).
4. Competitive sports participation may be considered
for an athlete with either previously symptomatic or
electrocardiographically evident BrS, early repolari-
zation syndrome, or short-QT syndrome assuming
appropriate precautionary measures and disease-
speciﬁc treatments are in place and that the athlete
has been asymptomatic on treatment for at least
3 months (Class IIb; Level of Evidence C). If therapy
includes an ICD, refer to the Task Force 9 report (2).
5. For an athlete with either symptomatic LQTS or elec-
trocardiographically manifest LQTS (i.e., corrected QT
interval >470 ms in males or >480 ms in females),
competitive sports participation (except competitive
swimming in a previously symptomatic LQT1 host)
may be considered after institution of treatment and
appropriate precautionary measures assuming the
athlete has been asymptomatic on treatment for at
least 3 months (Class IIb; Level of Evidence C). If
treatment includes an ICD, refer to the Task Force 9
report (2) for recommendations regarding restrictions
after the procedure, lead replacements, and so forth.
6. For an athlete with previously symptomatic CPVT or
an asymptomatic CPVT athlete with exercise-induced
premature ventricular contractions in bigeminy,
couplets, or nonsustained ventricular tachycardia,
participation in competitive sports is not recom-
mended except for class IA sports (Class III; Level of
Evidence C). Exceptions to this limitation should be
made only after consultation with a CPVT specialist.
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